<SEC-DOCUMENT>0000950170-22-010791.txt : 20220526
<SEC-HEADER>0000950170-22-010791.hdr.sgml : 20220526
<ACCEPTANCE-DATETIME>20220526171008
ACCESSION NUMBER:		0000950170-22-010791
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220526
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220526
DATE AS OF CHANGE:		20220526

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adicet Bio, Inc.
		CENTRAL INDEX KEY:			0001720580
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813305277
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38359
		FILM NUMBER:		22971238

	BUSINESS ADDRESS:	
		STREET 1:		200 CLARENDON  STREET
		STREET 2:		FLOOR 6
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-482-2333

	MAIL ADDRESS:	
		STREET 1:		200 CLARENDON  STREET
		STREET 2:		FLOOR 6
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	resTORbio, Inc.
		DATE OF NAME CHANGE:	20171024
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>acet-20220526.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-05-26T17:08:01.3833+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:acet="http://www.adicetbio.com/20220526">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_ff6fee33-81a2-4113-b031-6546e0a9b70b" name="dei:EntityCentralIndexKey" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b">0001720580</ix:nonNumeric><ix:nonNumeric id="F_d60ca6a0-c15b-4e04-b5ef-e884329b678c" name="dei:AmendmentFlag" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b">false</ix:nonNumeric><ix:nonNumeric id="F_35c57ac8-45d5-47dd-a92c-4b1c2391712a" name="dei:SecurityExchangeName" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b">NONE</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="acet-20220526.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_c8defc8f-8897-411c-b463-0b1e0b93096b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-26</xbrli:startDate><xbrli:endDate>2022-05-26</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="border-top:2.250pt double rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.75pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5d4e41e0-a797-496b-b3b2-8f2b3fb19022" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ade364bf-2895-4c87-8a97-d10cc77bdabc" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">May 26, 2022</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aee6b15e-f6dd-4ca0-ab63-01559e1eb344" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:24.0pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:19.399%;"></td>
    <td style="width:3.813%;"></td>
    <td style="width:19.399%;"></td>
    <td style="width:17.618%;"></td>
    <td style="width:39.772%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_274a256a-eb27-45e3-b198-eebcc2396c68" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_281380e6-af29-4ba7-88ee-9e68e198ba9e" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">001-38359</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0ff70e6b-074f-4536-b7b6-e7aed396b73a" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">81-3305277</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(State or Other Jurisdiction<br />of Incorporation)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(IRS Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e5de5828-2c98-415d-8aac-fc5f6b142951" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">200 Clarendon Street</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ecaeef7e-af46-4200-8cb6-d07628dc6a7c" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Floor 6</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e21d3227-653e-4170-8ec2-3119c9eadaaf" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Boston</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_842d3ec8-dfaf-4ad6-9c6a-5856e8e01d07" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f708c9ae-0fb8-4307-8336-e6cfe7fcd7f7" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">02116</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#x2019;s Telephone Number, Including Area Code:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_97b853f0-0bd5-41e8-ab7f-0a09f24de006" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae023259-7722-4003-91da-65b4192b5cd8" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">503-9095</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9.0pt;line-height:1.15;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_10a35cb3-2e94-4b71-9af2-096e2da505f2" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.15;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_84125085-ba3c-4395-a7e5-55abf6a89036" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.15;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b593f73-aa15-4928-8ff7-b643a7e5dcf5" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.15;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2d956a92-4040-46e7-bf3d-c8b2e3319152" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:37.996%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><br />Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Trading<br />Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><br />Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80e1d539-d397-4e67-9be8-41e028a511c1" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1d320926-f613-403a-a71f-22662a5c0a1d" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ACET</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_35c57ac8-45d5-47dd-a92c-4b1c2391712a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Nasdaq Global Market</span></span></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#x202f;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#x202f;240.12b-2 of this chapter).</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10.0pt;"><ix:nonNumeric id="F_b27e23d6-1a20-43e8-a283-b3bb22c0a42e" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10.0pt;"><ix:nonNumeric id="F_4af66b31-3bd8-43df-be57-95a0bbf5bda3" contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On May 26, 2022, Adicet Bio, Inc. (the &#x201c;Company&#x201d;) issued a press release titled &#x201c;Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin&#x2019;s Lymphoma (NHL),&#x201d; a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K .</span></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed &#x201c;filed&#x201d; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 8.01 Other Events.</span></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On May 26, 2022, the Company issued a press release announcing updated safety and efficacy data from the Company&#x2019;s Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin&#x2019;s Lymphoma (NHL). Data highlights as of the February 14, 2022 data-cut date were as follows:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Six evaluable patients were enrolled in dose level 1 (DL1; 30 million CAR+ cells) and dose level 2 (DL2; 100 million CAR+ cells), 33% (2/6) were female and the median age was 62 years (range 45-75). There were five patients with large B-cell lymphoma and one with mantle cell lymphoma. Indolent lymphomas, such as follicular lymphoma, are currently not enrolled in the study. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Overall, the patients were heavily pretreated with a median number of prior therapies of 3.5 (range 2-5) and had a poor prognostic outlook as indicated by the median International Prognostic Index (IPI) score of 3.5 (range 2-4). One patient previously progressed following two prior treatments with autologous anti-CD19 CAR T cell therapy (lisocabtagene maraleucel) prior to receiving ADI-001.  </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">At Day 28, the overall response rate (ORR) and the complete response (CR) rate based upon independent central reading by PET/CT were 67% (4/6 patients).</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of the February 14, 2022 data-cut date, of the four patients who achieved CR after treatment with ADI-001:</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.398746357288172%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Two patients remained in CR with &#x2265; three months post-treatment follow-up, including a triple-hit large B-cell lymphoma patient who had previously progressed following two administrations of autologous anti-CD19 CAR-T and a total of five lines of prior therapy.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.398746357288172%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As previously disclosed, one patient, a 66-year-old female who had responded to ADI-001, developed COVID-19 related pneumonia approximately two and a half months after ADI-001 administration and later died of complications from it, unrelated to ADI-001. This patient was previously reported as a partial response (PR) by local radiological assessment and has been assessed as a CR by independent central reading.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.398746357288172%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">One patient with a CR had not reached the three-month assessment date as of the data-cut date for the ASCO abstract submission. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Safety data from the trial at the February 14, 2022 data-cut date were consistent with the previously reported well tolerated profile, with no occurrence of Grade &#x2265; 3 </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cytokine Release Syndrome</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> (CRS), </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Immune Effector Cell-Associated Neurotoxicity Syndrome </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(ICANS) or </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Graft vs Host </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">D</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">isease</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. No dose-limiting toxicities were documented.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">All response data have been determined per protocol by independent central reading of PET/CT per Lugano (2014) criteria.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The disclosure under this Item 8.01 contains &#34;forward-looking statements&#34; of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to business and operations of Adicet. These forward-looking statements include, but are not limited to, express or implied statements regarding the potential safety, durability, tolerability and therapeutic effects of ADI-001; and the expectations around the upcoming release of interim clinical data from the Company&#x2019;s Phase 1 trial of ADI-001 in NHL patients. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of COVID-19 on Adicet&#x2019;s business and financial results, including with respect to disruptions to Adicet&#x2019;s clinical trials, business operations and ability to raise additional</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">capital; Adicet's ability to execute on its strategy, including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; clinical studies may fail to demonstrate adequate safety and efficacy of Adicet&#x2019;s product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization; and regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet's actual results to differ from those contained in the forward-looking statements, see the section entitled &#34;Risk Factors&#34; in Adicet's most recent Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent filings with the SEC. All disclosure under this Item 8.01 is as of the date of this Form 8-K, and Adicet undertakes no duty to update this information unless required by law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Exhibits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.0%;"></td>
    <td style="width:2.004%;"></td>
    <td style="width:87.996%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="/exhibit" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">99.1</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="acet-ex99_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Press Release of Adicet Bio, Inc. on May 26, 2022, furnished herewith.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6.002%;"></td>
    <td style="width:43.998%;"></td>
    <td style="width:6.002%;"></td>
    <td style="width:43.998%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.05;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Date:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">May 26, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Chen Schor</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Name:</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Title:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.7pt;line-height:1.05;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Chen Schor<br />President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>acet-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img94724212_0.jpg" alt="img94724212_0.jpg" style="width:310px;height:96px;">&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Exhibit 99.1</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:12.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin&#x2019;s Lymphoma (NHL)</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">As of the February 14, 2022 ASCO abstract data-cut date, ADI-001 demonstrated a 67% complete response rate with positive preliminary durability data and a favorable safety and tolerability profile</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Updated data from a May 31, 2022 data-cut date will be presented during oral presentation at ASCO Annual Meeting on June 6, 2022, at 6:00am PT / 9:00am ET</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Company to host webcast on June 6, 2022, at 1:30pm PT / 4:30pm ET</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Menlo Park, CA and Boston, MA &#x2013; May 26, 2022 &#x2013; Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that an abstract detailing updated safety and efficacy data from the Company&#x2019;s Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin&#x2019;s Lymphoma (NHL) was made available as part of the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 3-7, 2022. The abstract provides a summary of clinical data as of a February 14, 2022, data-cut date.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">&#x201c;We are very pleased to see the continued positive data resulting from our ongoing Phase 1 clinical trial evaluating ADI-001 in relapsed/refractory NHL. We believe that our allogeneic gamma delta CAR T cell therapy approach may improve complete response rate and durability by the complementary innate, adaptive and CAR-mediated anti-tumor response,&#x201d; said Chen Schor, President and Chief Executive Officer of Adicet. &#x201c;We look forward to presenting updated data on safety, efficacy, pharmacokinetics and longer follow up, including available data from patients enrolled in dose level 3, at the upcoming 2022 ASCO Annual Meeting with a coinciding press release as well as a company webcast later that afternoon.&#x201d;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Data highlights as of the February 14, 2022 data-cut date included in the ASCO abstract were as follows:</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Six evaluable patients were enrolled in dose level 1 (DL1; 30 million CAR+ cells) and dose level 2 (DL2; 100 million CAR+ cells), 33% (2/6) were female and the median age was 62 years (range 45-75). There were five patients with large B-cell lymphoma and one with mantle cell lymphoma. Indolent lymphomas, such as follicular lymphoma, are currently not enrolled in the study. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Overall, the patients were heavily pretreated with a median number of prior therapies of 3.5 (range 2-5) and had a poor prognostic outlook as indicated by the median International Prognostic Index (IPI) score of 3.5 (range 2-4). One patient previously progressed following </font></div></div>
  <hr style="page-break-after:always;">
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;visibility:hidden;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">two prior treatments with autologous anti-CD19 CAR T cell therapy (lisocabtagene maraleucel) prior to receiving ADI-001.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">At Day 28, the overall response rate (ORR) and the complete response (CR) rate based upon independent central reading by PET/CT were 67% (4/6 patients).</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">As of the February 14, 2022 data-cut date, of the four patients who achieved CR after treatment with ADI-001:</font></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Two patients remained in CR with &#x2265; three months post-treatment follow-up, including a triple-hit large B-cell lymphoma patient who had previously progressed following two administrations of autologous anti-CD19 CAR-T and a total of five lines of prior therapy.</font></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">As previously disclosed, one patient, a 66-year-old female who had responded to ADI-001, developed COVID-19 related pneumonia approximately two and a half months after ADI-001 administration and later died of complications from it, unrelated to ADI-001. This patient was previously reported as a partial response (PR) by local radiological assessment and has been assessed as a CR by independent central reading.</font></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">One patient with a CR had not reached the three-month assessment date as of the data-cut date for the ASCO abstract submission. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Safety data from the trial at the February 14, 2022 data-cut date were consistent with the previously reported well tolerated profile, with no occurrence of Grade &#x2265; 3 </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Cytokine Release Syndrome</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> (CRS), </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Immune Effector Cell-Associated Neurotoxicity Syndrome </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">(ICANS) or </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Graft vs Host </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">D</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">isease</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">. No dose-limiting toxicities were documented.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">All response data have been determined per protocol by independent central reading of PET/CT per Lugano (2014) criteria.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">The full abstract is available online on the </font><font><font style="background-color:rgba(0,0,0,0);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">ASCO website</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">.</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">   </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Updated data from a May 31, 2022 data-cut date will be presented during an oral presentation by Sattva Neelapu, M.D. Professor in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, at the ASCO Annual Meeting on June 6, 2022. Adicet will summarize the data from the May 31, 2022 data-cut date in a press release and provide additional information in a company webcast on June 6, 2022.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Details of the oral presentation are as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Abstract Number:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> 7509<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Abstract Title:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> A Phase 1 Study of ADI-001: Anti-CD20 CAR-engineered Allogeneic Gamma Delta (&#x3b3;&#x3b4;) T cells in Adults with B-cell malignancies<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Presenting Author:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> Sattva Neelapu, M.D., The University of Texas MD Anderson Cancer Center<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Session Type/Title:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> Clinical Science Symposium/ Beating Bad Blood: The Power of Immunotherapy in Hematologic Malignancies<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Date:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> Monday, June 6, 2022<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Time:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> 8:00 AM-9:30 AM CDT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Adicet Investor Webcast/ Conference Call Information</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">The Company will host a conference call and webcast on June 6, 2022, at 4:30 p.m. ET to discuss the results. The live webcast of the presentation can be accessed under &#x201c;Presentations &amp; Events&#x201d; in the investors section of the Company&#x2019;s website at www.adicetbio.com or by dialing (877) 800-3802 (domestic) or +1 (615) 622-8057 (international) and reference the conference ID 5466375. The archived webcast will be available on the Company's website beginning approximately two hours after the event.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">About ADI-001</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"><br></font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL.  ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated potent antitumor activity in preclinical models, leading to long-term control of tumor growth.  In April 2022, ADI-001 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of relapsed or refractory B-cell NHL.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">About the GLEAN Study </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"><br></font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">This Phase 1 study is an open-label, multi-center study of ADI-001 enrolling adults diagnosed with B-cell malignancies who have either relapsed, or are refractory to at least two prior regimens. The primary objectives of the study are to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ADI-001, and to determine optimal dosing as a monotherapy. The study is expected to enroll approximately 75 patients. For more information about the clinical study design, please visit </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Arial;min-width:fit-content;">www.clinicaltrials.gov</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> (</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Arial;min-width:fit-content;">NCT04735471</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">About Adicet Bio, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of &#x201c;off-the-shelf&#x201d; gamma delta T cells, engineered with CAR and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Arial;min-width:fit-content;">www.adicetbio.com</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Available Information</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Adicet announces material information to the public about the Company, its product candidates and clinical trials, and other matters through a variety of means, including filings with the U.S. Securities and Exchange Commission (SEC), press releases, public conference calls, webcasts, the investor relations section of the Company website at investor.adicetbio.com and the Company&#x2019;s Twitter account (@AdicetBio), in order to achieve broad, non-exclusionary distribution of information to the public and for complying with its disclosure obligations under Regulation FD.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">This press release contains &#34;forward-looking statements&#34; of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to business and operations of Adicet. These forward-looking statements include, but are not limited to, express or implied statements regarding the potential safety, durability, tolerability and therapeutic effects of ADI-001 and the expectations around the upcoming release of interim clinical data from Adicet&#x2019;s Phase 1 trial of ADI-001 in NHL patients at the ASCO Annual Meeting.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of COVID-19 on Adicet&#x2019;s business and financial results, including with respect to disruptions to Adicet&#x2019;s clinical trials, business</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">operations and ability to raise additional capital; Adicet's ability to execute on its strategy, including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; clinical studies may fail to demonstrate adequate safety and efficacy of Adicet&#x2019;s product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization; and regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet's actual results to differ from those contained in the forward-looking statements, see the section titled &#34;Risk Factors&#34; in Adicet's most recent Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent filings with the SEC. All information in this press release is as of the date of the release, and Adicet undertakes no duty to update this information unless required by law.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Adicet Bio, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Investor and Media Contacts</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Anne Bowdidge</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">abowdidge@adicetbio.com</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Janhavi Mohite</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">Stern Investor Relations, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">212-362-1200</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;">janhavi.mohite@sternir.com</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img94724212_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img94724212_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "; ?,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*R/$7B2P\,Z>;R_8A,X 7DFA*^@&O17!:3\6O#VL:C%8P"=9)3A2Z8%=X""
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
*%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>acet-20220526.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-05-26T17:08:01.2414+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.adicetbio.com/20220526" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:acet="http://www.adicetbio.com/20220526" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acet-20220526_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acet-20220526_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>acet-20220526_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-05-26T17:08:01.2783+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="acet-20220526.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10200.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>acet-20220526_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-05-26T17:08:01.3180+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140390823276952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>May 26, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 26,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adicet Bio, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001720580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-3305277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Clarendon Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Floor 6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">503-9095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACET<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NONE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>acet-20220526_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="acet-20220526.xsd" xlink:type="simple"/>
    <context id="C_c8defc8f-8897-411c-b463-0b1e0b93096b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2022-05-26</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_ff6fee33-81a2-4113-b031-6546e0a9b70b">0001720580</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_d60ca6a0-c15b-4e04-b5ef-e884329b678c">false</dei:AmendmentFlag>
    <dei:SecurityExchangeName
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_35c57ac8-45d5-47dd-a92c-4b1c2391712a">NONE</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_5d4e41e0-a797-496b-b3b2-8f2b3fb19022">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_ade364bf-2895-4c87-8a97-d10cc77bdabc">2022-05-26</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_aee6b15e-f6dd-4ca0-ab63-01559e1eb344">Adicet Bio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_274a256a-eb27-45e3-b198-eebcc2396c68">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_281380e6-af29-4ba7-88ee-9e68e198ba9e">001-38359</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_0ff70e6b-074f-4536-b7b6-e7aed396b73a">81-3305277</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_e5de5828-2c98-415d-8aac-fc5f6b142951">200 Clarendon Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_ecaeef7e-af46-4200-8cb6-d07628dc6a7c">Floor 6</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_e21d3227-653e-4170-8ec2-3119c9eadaaf">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_842d3ec8-dfaf-4ad6-9c6a-5856e8e01d07">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_f708c9ae-0fb8-4307-8336-e6cfe7fcd7f7">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_97b853f0-0bd5-41e8-ab7f-0a09f24de006">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_ae023259-7722-4003-91da-65b4192b5cd8">503-9095</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_10a35cb3-2e94-4b71-9af2-096e2da505f2">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_84125085-ba3c-4395-a7e5-55abf6a89036">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_0b593f73-aa15-4928-8ff7-b643a7e5dcf5">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_2d956a92-4040-46e7-bf3d-c8b2e3319152">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_80e1d539-d397-4e67-9be8-41e028a511c1">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_1d320926-f613-403a-a71f-22662a5c0a1d">ACET</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_b27e23d6-1a20-43e8-a283-b3bb22c0a42e">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_c8defc8f-8897-411c-b463-0b1e0b93096b"
      id="F_4af66b31-3bd8-43df-be57-95a0bbf5bda3">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M>QP@H=MPP@WDRR^/S['?<\)@)]6[WG)NR#Z.$CUTML:DGUU7!UL>,WTO4Y[
MG;54,3-PJC:N3A5G83XHCESJ>1TW9B)Q1H/\VER-!C(SD4CX7!&=Q3%3APF/
MY&[H^,[YPIO8;(V]X(X&*=OP!3=_I',%9VZA$HJ8)UK(A"B^'CIC__.$=NR
M_(D_!=_IBV-BI[*2\MV>/(5#Q[-$/.*!L1(,OC[XE$>150*.[R=1I_A-._#R
M^*S^F$\>)K-BFD]E]$V$9CMT>@X)^9IED7F3N]_Y:4)MJQ?(2.>?9'=\MM5R
M2)!I(^/38""(17+\9OM3("X'T"L#Z&D S;F//Y13/C##1@,E=T39IT'-'N13
MS4<#G$AL5A9&P5T!X\SH0089!-F0<1*266*$.9"GY)AMB-K -? C]E$W. E.
MCH+TBN S.Q#::1#J4?K?T2Z@%7RTX*.Y7/.*W%1^<$7^'J^T49#!?Q#)9B'9
MS"5;=5->'E)>-4%\>._N"P+1*B!:J,H8",*<XC%BFRH*?/R:19HC'.V"HWU;
M,.9<"6F70$A@(57&!5<Z)?ZG3Y]J4M\IT#JHX&DUOO&-L,D'QA<65X+A.N-0
M!&!O$R$;L+2#>P2M6Z!U;T&;0N 4BT UY'ORA1^JX' ES_/\+O7:/0_!ZA58
MO5NP9C%7&Y%LR&\PWFS)5,8I2RKA<#VC,FR-]0NL_BU8CR+BY"6+5UQ5H> :
M$*:[9J_9[B,\OE>:GG<+$:P&J5*I<JMKD(6!A4^D@H!ED%C(KPPKUUN-^L,,
M@[QP9O\6R"7;DZ<05II8BR G18)8(]F#(#:]-NUV,<+2FWUZ"^$X#!77NG$^
M(%_A.?*:5,<.EX1N@DPCIL =8:)P!PH;QEJ:OH_;-LJZW,E*5ESR,9*P6#H8
M7ED.?-S/?\2;VC-07\I==1'&Y282.H<$(RL+A(_[^H]DQ2Z9*_DADJ ZRS6U
M8HRAE07"OZE"%&ASF#78\5\BO;YU<46/^CZ:T+)"^+BQYPD<0Z-\'047Z+2Q
MDN"7-<''3?RK#" F\ZU,,/>M$6E[S;N^UV]C1&4Y\'$O_Z:$,3RQ=2G.DI.I
MZ4HJ7*BN":)E0:"X92]D) )A;-%\AN6M!(NJ>&I4:GE*[Z>X4<\5OPL@/!SV
MU[%7!4.$1OAUO:[.7XU>+=E%/XX;]/_(GK3.@*P6$)>M!2R-GMYD]+,]64+3
MJ$5>,8_=;247KE;+53H\Q2UY*0ST/W)-?/K+ZE>RX$$&^Z"R*ZM1LOLF+XXR
M>&^0E"GRP:*,DY^]>]M.DA3RH+=00S'NTO\I[M40Q=#NB\4A7LGJ78$+C*>S
M)492VCW%S?D<,LAML&7)AE]](:@1>GE]J6S1W(OW:/N?Q#.S?;0F$5^#CG??
MA8FJXVO^\<3(-'^U7DD#+^KYX98SV ?V ;B_EM*<3^S;>O%GR^A?4$L#!!0
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MDUM)Z.#<@V#OX96,'<V/'W?W U!+ P04    " !!B;I4)!Z;HJT   #X 0
M&@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I
M0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LID
MR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\
M./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6
M?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ 08FZ5&60>9(9 0
MSP,  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F
M&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\
M% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY
M&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J
M>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q
M32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1
MS>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4
M    " !!B;I4!T%-8H$   "Q    $               @ $     9&]C4')O
M<',O87!P+GAM;%!+ 0(4 Q0    ( $&)NE39W>%Z[@   "L"   1
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M96QS+RYR96QS4$L! A0#%     @ 08FZ5#JJHN=  0  / (   \
M     ( !9Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( $&)NE0D'INB
MK0   /@!   :              "  =01  !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( $&)NE1ED'F2&0$  ,\#   3
M  "  ;D2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(   ,4
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="acet-20220526.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="acet-20220526.htm">acet-20220526.htm</File>
    <File>acet-20220526.xsd</File>
    <File>acet-20220526_lab.xml</File>
    <File>acet-20220526_pre.xml</File>
    <File>acet-ex99_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "acet-20220526.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "acet-20220526.htm"
     ]
    },
    "labelLink": {
     "local": [
      "acet-20220526_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "acet-20220526_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "acet-20220526.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "acet",
   "nsuri": "http://www.adicetbio.com/20220526",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "acet-20220526.htm",
      "contextRef": "C_c8defc8f-8897-411c-b463-0b1e0b93096b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "role": "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "acet-20220526.htm",
      "contextRef": "C_c8defc8f-8897-411c-b463-0b1e0b93096b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adicetbio.com/20220526/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000950170-22-010791-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-010791-xbrl.zip
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M7?P149IX]'<2 _L'Q5X41. 4$>!TF9%"3*ND9"G/JB*9DX*5HHCG\LGZ@2P
M:*CL[+J)5+ZLY0=  +VP=-[\%H-TR:[Q.8Q?"4SF+]::$#]$$ZQ1K-43NHUD
MU+ D)VE$EJ3@^KN'>XL]0:]8(3N=3_?N?/$*L0A=8Z8=!B8UN&]1*W!UZK/8
MH*"!<B-BMF;'S^Z%^+^Y* 'V6-!1I75N?W$WSAED61(P0)@2T/9Y6_WS'WW7
MLO8>4D,[;;#44 /8M\%&9JW6;F<5J(N68=>$=ZNE&W9RV]9=,OYX1@Q3&\#
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MIM,M!1"Y"QI6)9&JQ#6P%ARN"F^[5VO;98/G1\"E4>3O5"*OM T8V(:WIF]
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M57+W6-;D<I@K.^:'._I.(DR7\DF_"(T8(VD^872N*N60W=$R(ZKH<M4!J2P
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MO6WE\&W1]ZL/\@R._Q'IZG]02P,$%     @ 08FZ5/)X0FBM!   ]R<  !4
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M@P\L*XL X7E2D_M$QD'<@MGD!3NLB6,B#&%]_J+&(E&6+(A+I2LY+<MD>;!
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M-;=A<!YI<P,>S_G"V##/SZ#[%KOOC]VUP-U(!H#D3XKASP^SL[ER>.FLXH5
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M]0B4<;SXE&ZQI21;2O*,*$G=7%Y8_.&((X% ER"<:3\25NTF$< C]*[C"H6
M5,$BRZ$A+FIW.23$Y..I- 90?>M=W.K9WR\%>5EZ]I6-]E\.\+>!MD7HY><"
MR<@6!QT:D!1*>D2^RC7\G4(P;98G22<VQ;-I7TH44[Z-;O#)3?BKQM#^4IWI
ML76>B_4@[/;[3?=_YYMD7"TR"H;%#',*.+U:) $ 5-Q_SM]PV]'X>K73W&2
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M?/F+K K=<_6L@7O\6NO &1AJM@D;ZKXZ PII6+JHQ(*!FME*JK!>.<.Q@'$
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M5RW=#:*ZV(94%N5%HEZ%+D[T@T@+W2?L2B^JY!8Y6"*FH20/3+6@U7'(?%#
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M*$W!5N()-/F4#*!DQ4SP#CRZ=RY/BCW!CJVEDKMPT$JC+')ZK9)\!ZVOZ]%
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M\GHWRJ;QS_\#4$L! A0#%     @ 08FZ5/6P6#9Y'0  =@X! !$
M     ( !     &%C970M,C R,C U,C8N:'1M4$L! A0#%     @ 08FZ5.="
MNXT- P  IPD  !$              ( !J!T  &%C970M,C R,C U,C8N>'-D
M4$L! A0#%     @ 08FZ5%*2!IS3!0  1S8  !4              ( !Y"
M &%C970M,C R,C U,C9?;&%B+GAM;%!+ 0(4 Q0    ( $&)NE3R>$)HK00
M /<G   5              "  >HF  !A8V5T+3(P,C(P-3(V7W!R92YX;6Q0
M2P$"% ,4    " !!B;I4>$B$0-X6   1I   #P              @ '**P
E86-E="UE>#DY7S$N:'1M4$L%!@     %  4 00$  -5"      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
